Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study
Φόρτωση...
Ημερομηνία
Συγγραφείς
Athyros, V. G.
Mikhailidis, D. P.
Didangelos, T. P.
Giouleme, O. I.
Liberopoulos, E. N.
Karagiannis, A.
Kakafika, A. I.
Tziomalos, K.
Burroughs, A. K.
Elisaf, M. S.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Current Medical Research and Opinion
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome (MetS). There is no established treatment for NAFLD. AIM: To evaluate a multifactorial intervention in the treatment of NAFLD. METHODS: A prospective, open-label, randomised study in non-diabetic patients (n = 186) with MetS (follow-up: 54 weeks). All patients had both biochemical and ultrasonographic evidence of NAFLD at baseline. Other causes of liver disease were excluded. Patients received lifestyle advice and treatment for hypertension (mainly inhibitors of the renin-angiotensin system), impaired fasting glucose (metformin), obesity (orlistat) and dyslipidaemia [randomly allocated to atorvastatin 20 mg/day (n = 63) or micronised fenofibrate 200 mg/day (n = 62) or both drugs (n = 61)]. Liver ultrasonography was assessed at baseline and at the end of the study. RESULTS: At the end of treatment, 67% of patients on atorvastatin, 42% on fenofibrate and 70% on combination treatment no longer had biochemical plus ultrasonographic evidence of NAFLD (p < 0.05 vs. baseline for all comparisons). The percentage of patients who no longer had evidence of NAFLD was significantly higher (p < 0.009) in the atorvastatin and combination groups compared with the fenofibrate group. This effect was independently related to drug treatment, as well as to reductions in high-sensitivity C-reactive protein, waist circumference, body weight, triglycerides, low-density lipoprotein-cholesterol, total cholesterol, systolic blood pressure and glucose. Four patients discontinued treatment because of adverse effects. CONCLUSIONS: Multifactorial intervention in MetS patients with both biochemical and ultrasonographic evidence of NAFLD offsets surrogate markers of NAFLD (i.e. elevated aminotransferase plus echogenic liver).
Περιγραφή
Λέξεις-κλειδιά
Anti-Obesity Agents/therapeutic use, Diet, Fat-Restricted, Drug Therapy, Combination, Dyslipidemias/drug therapy, Fatty Liver/*drug therapy/etiology/ultrasonography, Female, Fenofibrate/*therapeutic use, Heptanoic Acids/*therapeutic use, Humans, Hypolipidemic Agents/*therapeutic use, Lactones/therapeutic use, Male, Metabolic Syndrome X/*drug therapy/physiopathology, Middle Aged, Prevalence, Prospective Studies, Pyrroles/*therapeutic use, Risk Factors, Treatment Outcome, Weight Loss
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/16709309
http://informahealthcare.com/doi/abs/10.1185/030079906X104696
http://informahealthcare.com/doi/abs/10.1185/030079906X104696
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής